119 related articles for article (PubMed ID: 26542057)
21. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
Fujimori A; Hoki Y; Popescu NC; Pommier Y
Oncol Res; 1996; 8(7-8):295-301. PubMed ID: 8938793
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
23. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
24. An Explorative Analysis of
Stenvang J; Budinská E; van Cutsem E; Bosman F; Popovici V; Brünner N
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326511
[TBL] [Abstract][Full Text] [Related]
25. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
[TBL] [Abstract][Full Text] [Related]
26. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
27. Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Tsurutani J; Nitta T; Hirashima T; Komiya T; Uejima H; Tada H; Syunichi N; Tohda A; Fukuoka M; Nakagawa K
Lung Cancer; 2002 Mar; 35(3):299-304. PubMed ID: 11844605
[TBL] [Abstract][Full Text] [Related]
28. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.
Bosman FT; Yan P; Tejpar S; Fiocca R; Van Cutsem E; Kennedy RD; Dietrich D; Roth A
Clin Cancer Res; 2009 Sep; 15(17):5528-33. PubMed ID: 19690194
[TBL] [Abstract][Full Text] [Related]
29. Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.
Arakawa Y; Ozaki K; Okawa Y; Yamada H
Oncol Rep; 2013 Sep; 30(3):1053-8. PubMed ID: 23836376
[TBL] [Abstract][Full Text] [Related]
30. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
31. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
32. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
33. [Molecular determinants of response to topoisomerase I inhibitors].
Pourquier P; Lansiaux A
Bull Cancer; 2011 Nov; 98(11):1287-98. PubMed ID: 22049384
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase-I inhibitors in the management of colon cancer.
Willson JK
Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
[No Abstract] [Full Text] [Related]
36. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
37. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
[TBL] [Abstract][Full Text] [Related]
38. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
[TBL] [Abstract][Full Text] [Related]
39. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
[TBL] [Abstract][Full Text] [Related]
40. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Tentori L; Leonetti C; Muzi A; Dorio AS; Porru M; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Int J Oncol; 2013 Jul; 43(1):210-8. PubMed ID: 23653048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]